Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | APLNR | P35414 | 1/20 | 0.60 |
| ▸ | GLP1R | P43220 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 13/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871219 | 0.89 | NPSR1 (0.62) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2865932 | 0.87 | NPSR1 (0.59) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2867558 | 0.86 | NPSR1 (0.65) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2860846 | 0.86 | NPSR1 (0.65) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2867186 | 0.80 | NPSR1 (0.71) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2865324 | 0.79 | NPSR1 (1.00) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2864534 | 0.78 | NPSR1 (0.82) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2871588 | 0.78 | NPSR1 (0.69) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| SCHEMBL2868056 | 0.78 | NPSR1 (0.74) | NPSR1ADRB2APLNRGLP1RFFAR4 | |
| Hydrochloric Acid SCHEMBL2863758 | 0.77 | NPSR1 (0.73) | NPSR1ADRB2APLNRGLP1RFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885ADRB2 449/4885APLNR 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.